Journal of Cytokine Biology
Open Access

Therapeutic Monoclonal Antibodies Targeting Cytokine Storm: Inclusion as a Future Treatment for the Severe Cases of COVID-19

Shikha Patel¹, Bhagawati Saxena² and Priti Mehta^1*

¹Department of Pharmaceutical Analysis, Institute of Pharmacy, Nirma University,S.G. Highway, Ahmedabad, 382481, India

²Department of Pharmacology, Institute of Pharmacy, Nirma University, S.G. Highway, Ahmedabad, 382481, India

Received Date: Jul 05, 2021 / Accepted Date: Jul 19, 2021 / Published Date: Jul 27, 2021

Citation: Patel S, Saxena B, and Mehta P. (2021) Therapeutic Monoclonal Antibodies Targeting Cytokine Storm: Inclusion as a Future Treatment for the Severe Cases of COVID-19. J Cytokine Biol 6: 41.

Copyright: © 2021 Patel S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

To read the full article Peer-reviewed Article PDF

Clinical studies have manifested immunotherapeutics as the most propitious for the management of COVID-19 so far. However, the springing up variants of SARS CoV-2 has positioned the role of preventive immunotherapeutics – vaccines in doubt. Even so therapeutic monoclonal antibodies, Tocilizumab – an IL-6 inhibitor and Ravulizumab – a complement protein C5a blocker which are in clinical trial phase –IV are ascertained to be effectual for the COVID-19 cytokine storm and are envisioned to be included as an approved treatment for the severe COVID-19 cases.

Keywords